Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 2/20 | 0.45 |
| ▸ | PTAFR | P25105 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.41 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.41 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18288113 | 0.87 | ALDH1A1 (0.58) | ALDH1A1PTAFRACHEMAPK3MAPK1 | |
| SCHEMBL18555689 | 0.80 | ALDH1A1 (0.55) | ALDH1A1PTAFRACHEMAPK3MAPK1 | |
| SCHEMBL12191682 | 0.77 | ALDH1A1 (0.44) | ALDH1A1PTAFRACHEMAPK3MAPK1 | |
| SCHEMBL5386140 | 0.76 | KDM1A (0.57) | ALDH1A1PTAFRACHEMAPK3MAPK1 | |
| SCHEMBL1121729 | 0.76 | KMT2A (0.44) | ALDH1A1ACHEMAPK3MAPK1 | |
| SCHEMBL3690573 | 0.76 | PPARG (0.64) | ALDH1A1NR3C1 | |
| SCHEMBL15372462 | 0.76 | TUBB4A (0.56) | ALDH1A1MAPK1HIF1ATP53 | |
| SCHEMBL9778921 | 0.75 | KDM4E (0.49) | ALDH1A1FPR2MAPK1TP53 | |
| SCHEMBL3571617 | 0.75 | ALDH1A1 (0.47) | ALDH1A1PTAFRACHEMAPK3MAPK1 | |
| SCHEMBL6234654 | 0.74 | ALDH1A1 (0.48) | ALDH1A1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150376-A1 | Novel Sultam Compounds | PFIZER INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150376-A1 | Novel Sultam Compounds | PFIZER INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150376-A1 | Novel Sultam Compounds | PFIZER INC. (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2556076-A2 | NOVEL SULTAM COMPOUNDS | Pfizer Inc. (US) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011125006-A2 | NOVEL SULTAM COMPOUNDS | PFIZER INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011125006-A2 | NOVEL SULTAM COMPOUNDS | PFIZER INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| US-20110224231-A1 | Novel Lactams as Beta Secretase Inhibitors | PFIZER INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224231-A1 | Novel Lactams as Beta Secretase Inhibitors | PFIZER INC. (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224231-A1 | Novel Lactams as Beta Secretase Inhibitors | BACE1, BACE2, APH1B | ALDH1A1 2135/4885FPR2 3915/4885PTAFR 584/4885 |
| US-20130150376-A1 | Novel Sultam Compounds | SULT2A1, SULT1A1, SULT1E1 | ALDH1A1 75/4885FPR2 4079/4885PTAFR 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.